

Australian Government

Department of Health

Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	348334	GastroDaily	
ARTG entry for	Medicine Listed		
Sponsor	Medlab Pty Ltd		
Postal Address	PO Box 6452, Al Australia	LEXANDRIA, NSW, 2015	
ARTG Start Date	13/11/2020		
Product Category	Medicine		
Status	Active		
Approval Area	Listed Medicines	3	
O an all the ma			

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1. GastroDaily	I				
Product Type	Single Medicine Product	Effective Date	3/08/2021		
Permitted Indication	ons				
Maintain/support general health and wellbeing					
Decrease/reduce/relieve bowel discomfort					
Decrease/reduce/relieve diarrhoea					
Relief of symptoms of medically diagnosed Irritable Bowel Syndrome					
Maintain/support gastrointestinal system health					
Maintain/support healthy gastrointestinal function					
Decrease/reduce/relieve abdominal bloating/distention					
Decrease/reduce/relieve abdominal cramping					
Helps reduce occurrence of abdominal spasm					
Maintain/support immune system health					
Maintain/support healthy gastrointestinal immune function					
Indication Require	ments				
Label statement: If symptoms persist or worsen talk to your medical practitioner.					
Label statement: If symptoms persist, talk to your health professional.					
Label statement: Seek medical advice if diarrhoea persists for more than: 6 hours in infants under 6 months, 12 hours in children under 3 years, 24 hours in children aged 3 to 6 years or 48 hours in adults and children over 6 years (or words to that effect).					
Product presentation must only refer to medically diagnosed IBS.					

Product presentation must not imply or refer to gastro oesophageal reflux disease.

Product presentation must not imply or refer to serious immunological diseases.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

If diarrhoea persists for more than 6 hours in infants under 6 months, 12 hours in children under 3 years, 24 hours in children aged 3-6 years or 48 hours in

Page 1 of 2

This is not an ARTG Certificate document.

Produced at 31.08.2021 at 05:57:30 AEST

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown. Visit www.tga.gov.au for contact information



Australian Government

Department of Health

Therapeutic Goods Administration

adults and children over 6 years, seek medical advice (or words to that effect).

If symptoms persist consult your healthcare practitioner (or words to that effect).

Additional Product information

Container information							
Туре	Mater	rial	Life Time	Temperature	Closure	Conditions	
Multiple containers	Not recorded		Not recorded	Not recorded	Not recorded	Not recorded	
Pack Size/Poison information							
Pack Size				Poison Schedule			
Components							
1. Formulation 1							
Dosage Form		Powder					
Route of Administra	ation	Oral					
Visual Identification	n						
Active Ingredients							
glutamine				333.33 mg/g			
Larix arabinogalactan			333.33	333.33 mg/g			
Saccharomyces cerevisiae (Boulardii)					41.667	41.667 mg/g	
Other Ingredients (Excipients)							
cocoa powder							
colloidal anhydrous	s silica						
Flavour							
maltodextrin							
Peppermint Oil							
Stevia rebaudiana							

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown. Visit www.tga.gov.au for contact information

This is not an ARTG Certificate document.